KRTL Holding Announces KRTL Biotech Facilitates FDA Registration of SIGMACORP as a U.S. Pharmaceutical Manufacturer
KRTL Holding Group's subsidiary, KRTL Biotech, has successfully registered SIGMACORP with the FDA as a U.S. pharmaceutical manufacturer. Acting as SIGMACORP's U.S. Registered Agent, KRTL Biotech aims to facilitate international pharmaceutical integration and diversify the U.S. healthcare supply chain.
This registration enables SIGMACORP to manufacture pharmaceutical products for the U.S. market, potentially introducing more affordable healthcare solutions. The partnership focuses on expanding market opportunities, enhancing competitive advantages, and supporting U.S. healthcare resilience through supply chain diversification.
The milestone strengthens U.S.-Bolivia relations in the healthcare sector and positions KRTL Biotech as a leader in international pharmaceutical collaboration.
La sussidiaria del KRTL Holding Group, KRTL Biotech, ha registrato con successo SIGMACORP presso la FDA come produttore farmaceutico negli Stati Uniti. Operando come Agente Registrato di SIGMACORP, KRTL Biotech mira a facilitare l'integrazione farmaceutica internazionale e diversificare la catena di approvvigionamento sanitaria negli Stati Uniti.
Questa registrazione consente a SIGMACORP di produrre prodotti farmaceutici per il mercato statunitense, potenzialmente introducendo soluzioni sanitarie più accessibili. La partnership si concentra sull'ampliamento delle opportunità di mercato, sul potenziamento dei vantaggi competitivi e sul supporto della resilienza del sistema sanitario statunitense attraverso la diversificazione della catena di approvvigionamento.
Questo traguardo rafforza le relazioni tra Stati Uniti e Bolivia nel settore sanitario e posiziona KRTL Biotech come leader nella collaborazione farmaceutica internazionale.
La filial del KRTL Holding Group, KRTL Biotech, ha registrado con éxito a SIGMACORP ante la FDA como fabricante farmacéutico en EE. UU. Actuando como Agente Registrado de SIGMACORP, KRTL Biotech busca facilitar la integración farmacéutica internacional y diversificar la cadena de suministro de atención médica en EE. UU.
Este registro permite a SIGMACORP fabricar productos farmacéuticos para el mercado estadounidense, lo que podría introducir soluciones de atención médica más asequibles. La asociación se centra en expandir las oportunidades de mercado, mejorar las ventajas competitivas y apoyar la resiliencia del sistema de salud estadounidense a través de la diversificación de la cadena de suministro.
Este hito fortalece las relaciones entre EE. UU. y Bolivia en el sector de la salud y posiciona a KRTL Biotech como líder en colaboración farmacéutica internacional.
KRTL 홀딩 그룹의 자회사인 KRTL 바이오텍은 SIGMACORP를 FDA에 미국 제약 제조업체로 성공적으로 등록했습니다. SIGMACORP의 미국 등록 대리인 역할을 하는 KRTL 바이오텍은 국제 제약 통합을 촉진하고 미국의 의료 공급망을 다양화하는 것을 목표로 하고 있습니다.
이번 등록을 통해 SIGMACORP는 미국 시장을 위한 제약 제품을 제조할 수 있게 되어, 보다 저렴한 의료 솔루션을 도입할 가능성이 있습니다. 이 파트너십은 시장 기회를 확대하고 경쟁 우위를 강화하며, 공급망 다양화를 통해 미국 의료 시스템의 회복력을 지원하는 데 중점을 두고 있습니다.
이번 이정표는 미국과 볼리비아 간의 의료 분야 관계를 강화하고 KRTL 바이오텍을 국제 제약 협력의 선두주자로 자리잡게 합니다.
La filiale du KRTL Holding Group, KRTL Biotech, a enregistré avec succès SIGMACORP auprès de la FDA en tant que fabricant pharmaceutique aux États-Unis. Agissant en tant que Agent Enregistré de SIGMACORP, KRTL Biotech vise à faciliter l'intégration pharmaceutique internationale et à diversifier la chaîne d'approvisionnement en soins de santé aux États-Unis.
Cette inscription permet à SIGMACORP de fabriquer des produits pharmaceutiques pour le marché américain, ce qui pourrait introduire des solutions de santé plus abordables. Le partenariat se concentre sur l'élargissement des opportunités de marché, le renforcement des avantages concurrentiels et le soutien de la résilience du système de santé américain grâce à la diversification de la chaîne d'approvisionnement.
Ce jalon renforce les relations entre les États-Unis et la Bolivie dans le secteur de la santé et positionne KRTL Biotech en tant que leader de la collaboration pharmaceutique internationale.
Die Tochtergesellschaft der KRTL Holding Group, KRTL Biotech, hat SIGMACORP erfolgreich bei der FDA als US-Pharmahersteller registriert. Als Registrierter Agent von SIGMACORP hat KRTL Biotech das Ziel, die internationale pharmazeutische Integration zu erleichtern und die Lieferkette im Gesundheitswesen in den USA zu diversifizieren.
Diese Registrierung ermöglicht es SIGMACORP, pharmazeutische Produkte für den US-Markt herzustellen, was möglicherweise erschwinglichere Gesundheitslösungen zur Folge hat. Die Partnerschaft konzentriert sich darauf, Marktchancen zu erweitern, Wettbewerbs-vorteile zu stärken und die Resilienz des amerikanischen Gesundheitssystems durch Diversifizierung der Lieferkette zu unterstützen.
Dieser Meilenstein stärkt die Beziehungen zwischen den USA und Bolivien im Gesundheitssektor und positioniert KRTL Biotech als Führer in der internationalen pharmazeutischen Zusammenarbeit.
- FDA registration approval enables access to U.S. pharmaceutical market
- Strategic position to introduce cost-efficient pharmaceutical products
- Supply chain diversification potential through new manufacturing capabilities
- New revenue opportunities through international pharmaceutical partnerships
- None.
Lakewood, CO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) announces that its subsidiary, KRTL Biotech Inc., has successfully registered Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMACORP) with the U.S. Food and Drug Administration (FDA) as a U.S. pharmaceutical manufacturer. Acting as the U.S. Registered Agent for SIGMACORP, KRTL Biotech marks a significant step in facilitating international pharmaceutical integration and diversifying the U.S. healthcare supply chain.
Strategic Milestone in Global Pharmaceutical Collaboration
The FDA registration represents a pivotal achievement in KRTL Biotech’s ongoing efforts to bridge international pharmaceutical innovation with U.S. regulatory standards. This development creates opportunities to introduce cost-efficient, high-quality pharmaceutical products into the U.S. market while strengthening KRTL’s position in fostering global partnerships.
Key implications include:
- Expanding Market Opportunities: With SIGMACORP now approved to manufacture for the U.S., the partnership is positioned to support the introduction of affordable and reliable pharmaceutical products, addressing critical market needs.
- Enhancing Competitive Edge: This registration underscores KRTL Biotech’s role as a leader in international pharmaceutical collaboration, enabling the company to develop long-term strategic alliances and revenue opportunities.
- Supporting U.S. Healthcare Resilience: By broadening the pharmaceutical supply chain, this initiative provides diverse sources for active pharmaceutical ingredients (APIs) and finished products, contributing to supply chain sustainability and innovation.
A Strengthened Relationship Between the U.S. and Bolivia
This milestone also signifies an important moment for U.S.-Bolivia relations in the healthcare sector. By facilitating the entry of SIGMACORP into the U.S. market, KRTL Biotech demonstrates a commitment to advancing global healthcare solutions and addressing shared challenges.
COO’s Remarks
“We are grateful to KRTL Biotech for their partnership and their collaboration in achieving this milestone,” said Gary Gonzales Wilstermann, COO of SIGMACORP. “Our FDA registration as a U.S. pharmaceutical manufacturer underscores our commitment to delivering high-quality, cost-effective healthcare solutions globally. This achievement strengthens the U.S. pharmaceutical supply chain, highlights international collaboration, and represents Bolivia proudly on the global stage. We remain dedicated to addressing unmet medical needs, improving patient outcomes, and driving meaningful change in healthcare.”
Impacts on the U.S. Healthcare System
The FDA registration brings tangible benefits to the U.S. healthcare ecosystem, including:
- Increased Supply Chain Diversification: Reducing dependence on traditional markets and mitigating supply risks.
- Cost Savings: Introducing competitively priced pharmaceutical products to alleviate financial pressures in the healthcare system.
- Promoting Innovation: Supporting global knowledge exchange and technological advancements in pharmaceutical manufacturing.
CEO’s Remarks
“This accomplishment reflects our dedication to creating meaningful global partnerships that address critical healthcare needs,” said Cesar Herrera, CEO of KRTL Holding Group, Inc. “Facilitating SIGMACORP’s FDA registration exemplifies our vision of leveraging international collaboration to deliver innovative and cost-effective solutions to the U.S. market.”
About SIGMACORP
Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMACORP) is a leading Bolivian pharmaceutical manufacturer committed to providing high-quality healthcare solutions. Its FDA registration opens pathways to expand its reach, bringing innovative products to the U.S. market through collaboration with KRTL Biotech.
About KRTL Holding Group, Inc.
We are interested in having a competitive edge in the marketplace, through mergers & acquisitions, collaborations, and strategic alliances with specific partners.
KRTL Holding Group Inc., a holding company which operates through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries have evolved to focus on distinct industries, yet they intricately intertwine, forming the bedrock of the KRTL brand. This strategic synergy empowers KRTL Holding Group to actively pursue investment opportunities and forge invaluable partnerships, ultimately enhancing shareholder value.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
FAQ
What did KRTL Biotech achieve with SIGMACORP's FDA registration in December 2023?
How will SIGMACORP's FDA registration benefit KRTL stock (KRTL)?
What are the main business advantages of KRTL's partnership with SIGMACORP?
